Modified ADAMTS4 molecules and method of use thereof

a technology of aggrecanase and adamts4, which is applied in the field of modified aggrecanases, can solve the problems of hampered research effects on adamts4 and achieve the effects of facilitating the production of anti-adamts antibodies, reducing binding affinity, and improving stability

Inactive Publication Date: 2006-10-12
WYETH LLC
View PDF22 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] The present invention is based on the observation that the full-length, furin-processed ADAMTS4 molecules are capable of undergoing auto-catalytic C-terminal truncation. The auto-digested ADAMTS4 molecules exhibited markedly reduced affinity of binding to sulfated glycosaminoglycans (GAGs) but retained aggrecanase activity. Further studies revealed that ADAMTS molecules with modified domain structures can be enzymatically active while having improved stability compared to the native enzyme. For example, it was found that modified ADAMTS4 molecules with truncated spacer domain or no spacer domain are biologically active and are more stable than their full-length counterparts. The modified ADAMTS proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also facilitate the production of anti-ADAMTS antibodies and the development of inhibitors to ADAMTS enzymes.
[0008] One aspect of the present invention pertains to modified ADAMTS4 (mTS4) proteins; nucleotide sequences which encode mTS4 proteins; and processes for the production of mTS4 proteins. Preferably, the mTS4 proteins of the present invention are more stable and can be expressed at levels higher than that of their full-length counterparts. More preferably, the mTS4 proteins of the present invention are more stable and biologically active.

Problems solved by technology

However, research effects on ADAMTS4 have been hampered by the instability of purified ADAMTS4 proteins.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified ADAMTS4 molecules and method of use thereof
  • Modified ADAMTS4 molecules and method of use thereof
  • Modified ADAMTS4 molecules and method of use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Cloning and Purification of Full-Length Human ADAMTS4

[0118] Human ADAMTS4 cDNA was cloned using a PCR strategy. Two sets of oligonucleotide primers were designed to amplify overlapping portions of the 5′- and 3′-halves of the cDNA. Of the seven human multiple-tissue cDNA libraries that were used as PCR templates, only the uterus cDNA library resulted in PCR products of the appropriate size (5′-amplimer of 1294bp (SEQ ID NO:2) and 3′-amplimer of 1421bp (SEQ ID NO:3)). PCR-amplified fragments were digested with EcoRI and BamHI (5′-product) or BamHI and NotI (3′-product), ligated into EcoRI- and NotI-digested COS expression vector pED6-dpc2, and transformed into ElectroMAX DH10B cells (Invitrogen). Cloned PCR fragments of ADAMTS4 were sequenced and found to have three silent changes as compared with the published nucleotide sequence for ADAMTS4 cDNA (SEQ ID NO:4) (Tortorella et al., Science 284:1664-1666, 1999). These changes were C to T at base pair 466, A to G at base pair 2131, and...

example 2

Generation of Truncated ADAMTS4 Molecules by Auto-Digestion

[0121] Purified recombinant human ADAMTS4 migrated on SDS-PAGE gels predominantly as a 68 kD band, together with a small amount (2 and 0.1-1.0M NaCl. Auto-digested products were visualized by Coomassie blue staining, by silver staining, or by Western immunoblot analysis with the L9026 antibody.

[0122] Following incubation at 37° C. for various times up to 16 h, ADAMTS4 was detected as isoforms of 68 kD (ADAMTS4(p68)), 53 kDa (ADAMTS4(p53)) and 40 kD (ADAMTS4(p40)). Results from incubations performed using ADAMTS4 at concentrations ranging from 10 pg / ml to 569 pg / ml, and at salt concentrations up to 1.0M, were essentially identical. Incubation of ADAMTS4 ASM under the same condition resulted in no detectable isoforms, thus confirming that the processing of ADAMTS4 was autocatalytic (Flannery et al., J. Biol. Chem. 277:42775-42780).

example 3

Amino Acid Sequencing and Mass Spectrometry Analyses of Auto-Digested ADAMTS4 Isoforms

[0123] For N-terminal sequence analysis, aliquots of auto-digested ADAMTS4 isoforms were separated on 10% Bis-Tris NuPage SDS-PAGE gels and transferred to PVDF membranes which were stained with Coomassie blue. Excised bands corresponding to ADAMTS4(p68), ADAMTS4(p53) and ADAMTS4(p40) were subjected to automated sequencing on a PE-Biosystems 491A Pulsed-Liquid Sequencer on-line with a PE-Biosystems 140S PTH Analyzer (Procise-HT).

[0124] For C-terminal sequence analysis, auto-digested ADAMTS4 isoforms were separated by fractionation on a column of Poros HQ. Unbound ADAMTS4(p53) and ADAMTS4(p40) were subsequently fractionated on a column of Poros HS eluted using an isocratic gradient of 0.05-1.0 M NaCl in 25mM HEPES, pH 6.8, 5 mM CaCl2 and 5 pM ZnCl2. Mass spectrometry analyses were performed using a Micromass LCT (LC-TOF-MS) analyzer (Micromass UK, Ltd, Manchester, U.K.). Samples were concentrated a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also facilitate the production of anti-ADAMTS antibodies and the development of inhibitors to ADAMTS enzymes.

Description

RELATED APPLICATIONS [0001] This application claims the benefit of priority of U.S. Provisional Patent Application Ser. No. 60 / 398,721, filed Jul. 29, 2002, the entire disclosure of which is incorporated by reference herein.FIELD OF THE INVENTION [0002] The present invention relates to modified aggrecanases, nucleotides encoding such enzymes, and processes for producing these enzymes. The invention further relates to the development of inhibitors of, as well as antibodies to, the modified aggrecanase. These inhibitors and antibodies may be useful for the treatment of various aggrecanase-associated conditions including osteoarthritis. BACKGROUND OF THE INVENTION [0003] Aggrecan is a major extracellular component of articular cartilage. It is a proteoglycan responsible for providing cartilage with its mechanical properties of compressibility and elasticity. The loss of aggrecan has been implicated in the degradation of articular cartilage in arthritic diseases such as osteoarthritis. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395G01N33/53C07H21/04C12P21/06C07K14/705A61K45/00G01N33/50A61P19/00A61P19/02A61P43/00C12N9/64C12N15/09C12Q1/37G01N33/15
CPCC12N9/6489A61K2039/505A61P19/00A61P19/02A61P43/00
Inventor CORCORAN, CHRISTOPHERFLANNERY, CARLZENG, WEILANRACIE, LISAMCDONAGH, THOMASFREEMAN, BETHANYGEORGIADIS, KATYLAVALLIE, EDWARD
Owner WYETH LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products